PPARG and Parkinson disease: Multiple preclinical investigations have demonstrated that peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists facilitate microglial shift toward the anti-inflammatory M2 phenotype, potentially mitigating neuronal damage in PD (150).